I am sure that the 2b/3 trial has yielded some complexities. The tipoffs are the combined dose arms (titration/dropout issues?) and the unusual endpoint measurements (to handle nonstandard response curves?). Additionally, Missling has previously noted the genomic study will be used for context, and this morning produced an interesting list of other AD symptoms to be analyzed. So, even as a Phase 3 this is complicated.
Market Data 
Markets 
